A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
A phase 3 trial of Teclistamab, Daratumumab, Lenalidomide in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT05552222 by Janssen Research & Development, LLC, with 1590 participants planned, started 2022-10-25 and due to reach its primary completion in 2031-04-30. Interventions recorded: Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
Shares Talquetamab, Teclistamab, Daratumumab, Lenalidomide.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Talquetamab, Daratumumab, Dexamethasone, Johnson & Johnson.
- TrialA Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Talquetamab, Teclistamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
Shares Daratumumab, Dexamethasone, Lenalidomide, Johnson & Johnson.
- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Talquetamab, Teclistamab, Dexamethasone, Johnson & Johnson.
- TrialA Study of Daratumumab
Shares Daratumumab, Dexamethasone, Lenalidomide, Johnson & Johnson.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.